Opinion|Videos|July 23, 2024
Empowering Patients: Key Considerations for BTK Inhibitor Adherence
A conversation on how to empower patients and the considerations for BTK inhibitor adherence.
Advertisement
Episodes in this series
Video content above is prompted by the following question(s):
- What are the key considerations for educating and empowering patients about BTK inhibitors to support adherence for the course of long-term treatment?
Advertisement
Related to this article
Even when physicians prescribe guideline-preferred therapies, step therapy and prior authorization can delay or restrict access to CLL therapies.
Advertisement
Advertisement
Trending on AJMC
1
MASH Fibrosis, Not Resolution, Predicts Mortality: Zobair Younossi, MD
2
FDA Approves Once-Monthly Subcutaneous Olanzapine for Schizophrenia
3
5 Things to Know if Retatrutide Is Classified as a Biologic
4
NEI Director Highlights Pediatric Advances, AI’s Promise in Eye Care
5